[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
August 6, 2008

Balancing Disclosure of Diagnosis and Assent for Research in Children With HIV

Author Affiliations

Author Affiliations: Department of Oncology (Drs Barfield and Kane), Palliative and End-of-Life Care Program (Dr Kane), and Ethics Committee (Drs Barfield and Kane), St Jude Children's Research Hospital, Memphis, Tennessee. Dr Barfield is now with Duke University, Durham, North Carolina.

JAMA. 2008;300(5):576-578. doi:10.1001/jama.300.5.576

Children comprise a large subgroup of patients with human immunodeficiency virus (HIV) infection, and their treatment must be defined by pediatric clinical trials. Children's participation in research trials requires the fully informed consent of the parent or legal guardian,1 to whom most of the information is commonly directed.2 However, for nontherapeutic trials, the Code of Federal Regulations also requires that assent (the “affirmative agreement to participate in research”) be obtained from children at appropriate developmental ages.3 It also assigns to institutional review boards (IRBs) the duty to “determine that adequate provisions are made for soliciting the assent of the children . . . capable of providing assent.”3

First Page Preview View Large
First page PDF preview
First page PDF preview
×